SAN DIEGO (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized the repurchase of up to $500 million of the firm's common stock during fiscal year 2013.

The company said that the new repurchase program replaces an existing stock repurchase program that had authorized the repurchase of shares to eliminate or reduce share dilution from equity programs.

Agilent finished its 2012 fiscal year on Oct. 31, 2012. It held $2.35 billion in cash and cash equivalents as of that date.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.